Neuroscience Grand Rounds 2025 - 1/31/2025 Redefining Neurodegeneration: Beyond the Century-Old Clinicopathologic Model

Friday, January 31, 2025, 8:00 AM - 9:00 AM, Other, Tucson, AZ


AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician Attendance (1.00 hours)

Neuroscience Grand Rounds provides speakers who provide clinical information as well as ground-breaking research in basic neurosciences. This scientific and clinical correlation allows the audience of this activity to see ways to incorporate new basic knowledge into clinical practice.

Objective(s): 1 • To discuss the biophysics of soluble-to-insoluble phase transformation of brain proteins and the basis of proteinopenia in neurodegeneration 2 • To review data from anti-Aß monoclonal antibody trials for Alzheimer’s disease and consider a shift in disease-modifying efforts toward protein replacement strategies. 3 To review the pitfalls in the prevailing gain of function (proteinopathy) model of Alzheimer's and Parkinson's diseases.
Location: Other
Specialties: Neurology

Faculty Disclosures:
Alberto Espay, MD (Advisor-Acadia|Advisor-Acordia|Advisor-Amneal|Advisor-Avion|Advisor-Bexion|Advisor-Herantis|Advisor-Kyowa Kirin|Advisor-Neuroderm|Advisor-Praxis|Advisor-Sunovion Pharmaceuticals, Inc.|Advisor-Supernus Pharmaceuticals, Inc.|Consulting Fee-Acadia|Consulting Fee-Acorda|Consulting Fee-Amneal|Consulting Fee-Bexion|Consulting Fee-Herantis|Consulting Fee-Kyowa Kirin|Consulting Fee-Neuroderm|Consulting Fee-Praxis|Consulting Fee-Sunovion Pharmaceuticals, Inc.|Consulting Fee-Supernus Pharmaceuticals, Inc.|Grant or research support-Michael J Fox Foundation|Grant or research support-NIH|Royalties or Patent Beneficiary-Cambridge University Press,|Royalties or Patent Beneficiary-Lippincott Williams & Wilkins|Royalties or Patent Beneficiary-Springer|Royalties or Patent Beneficiary-REGAIN Therapeutics - 01/09/2025)
Download Handout

1. • To discuss the biophysics of soluble-to-insoluble phase transformation of brain proteins and the basis of proteinopenia in neurodegeneration
2. • To review data from anti-Aß monoclonal antibody trials for Alzheimer’s disease and consider a shift in disease-modifying efforts toward protein replacement strategies.
3. To review the pitfalls in the prevailing gain of function (proteinopathy) model of Alzheimer's and Parkinson's diseases.

The University of Arizona College of Medicine - Tucson is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Arizona College of Medicine - Tucson designates this Live Activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Refund and Cancellation Policy

A full refund will be issued for requests received up to 7 days prior to the conference.
No refund will be provided once the conference begins.

The organization holding the activity reserves the right to cancel or postpone this program if necessary; in the event of cancellation, registration fees will be fully refunded. We are not responsible for other costs incurred such as non-refundable airline tickets or hotel penalties.

Accessibility Statement
 
University of Arizona College of Medicine - Tucson Office of Continuing Medical Education is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require special accommodations, including dietary concerns, please contact the CME activity coordinator.

Mitigation of Relevant Financial Relationships

University of Arizona College of Medicine - Tucson Office of Continuing Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). The CME office reviewers have nothing to disclose. All relevant financial relationships have been mitigated prior to the commencement of the activity.

Date	Empty Column	Title
		No activities are currently published for this month.
No upcoming dates have been setup.